Pazopanib/pazopanib efficacy and side effects

Pazopanib/Pazopanib is a multi-kinase inhibitor that mainly works by targeting multiple receptors such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and c-KIT, thereby inducing anti-angiogenic effects, effectively inhibiting tumor growth and promoting cell apoptosis. Currently, the U.S. Food and Drug Administration (FDA) has approved pazopanib for the treatment of advanced renal cell carcinoma and difficult-to-treat soft tissue sarcomas.

As a second-generation multi-target tyrosine kinase inhibitor, pazopanib targets multiple receptors such asVEGFR-1, -2 and -3, PDGFR-α, PDGFR-β and c-kit, showing excellent anti-angiogenesis and anti-tumor activity, and also exhibits synergistic effects with chemotherapy drugs. Preclinical evaluation results show that pazopanib exhibits significant anti-tumor activity in animal models of multiple tumors, accompanied by ideal pharmacokinetics and oral bioavailability. Ongoing trials are also ongoing to further evaluate the efficacy of pazopanib in various malignancies.

However, pazopanib may cause some common side effects during use, including fatigue, diarrhea, hypertension, hair color changes, anorexia, nausea, and bone marrow suppression. In addition, there are some less common but potentially serious side effects, such as QTc prolongation, bleeding, arterial thrombosis, visceral perforation and fistulas, interstitial lung disease, reversible posterior leukoencephalopathy syndrome, and embryo-fetal toxicity. Therefore, while using pazopanib, patients need to monitor closely and promptly report any discomfort or abnormalities to their doctors so that the treatment plan can be adjusted in a timely manner to ensure the safe and effective use of the drug.